The overall goal in this SCOR grant is to study aspects of interaction of PTH and estrogen in the pathogenesis and treatment of osteoporosis. The function of the Core is to provide the technical tools to investigators to answer the questions posed. The Biochemistry Core has served this purposed in the last grant funding period and will continued, in concert with the other Cores, to provide investigators with the state-of-the-art tools to understand and solve this insidious disease. While the improvement in the precision and accuracy of bone mass measurement in recent years has enabled the investigator to make the diagnosis, and follow the progress of the disease with certain confidence, a relatively long period of time is still needed to observe changes. Histomorphometric measurements provide significant insight into the state of bone turnover, however, the invasive nature of bone biopsy, and the limitations on the frequency of follow up samples, restricts the use of this technique. In recent years, biochemical markers, relevant to the bone loss process, have become readily available. Some of these markers have been correlated to histomorphometric parameters of bone turnover. Although a single determination of these markers cannot generally be used to replace bone mass measurement, a series of marker determinations from the same individual within a short period of time has proven to be very useful in monitoring the efficacy of drug intervention or degree of compliance. In addition, the use of biochemical markers in conjunction with bone mass has enhanced the ability to predict fracture risk. In this application, the Biochemistry Core will perform calcium metabolism, bone turnover markers, and cytokine assays for each of the projects. Cytokines will be used to aid the study of subcellular mechanism of PTH action in a mouse models, pathogenesis and treatment of hyperparathyroidism in humans and has a main tool to study the efficacy of short term intermittent PTH treatment, its subsequent withdrawal and rechallenge.

Project Start
1999-09-01
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Helen Hayes Hospital
Department
Type
DUNS #
157119244
City
Menands
State
NY
Country
United States
Zip Code
12204
Ascenzi, Maria-Grazia; Liao, Vivian P; Lee, Brittany M et al. (2012) Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. J Bone Miner Res 27:702-12
Zhang, Hao; Doty, Stephen B; Hughes, Christine et al. (2007) Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. J Cell Biochem 102:1011-20
Dempster, David W; Hughes-Begos, Christine E; Plavetic-Chee, Katarina et al. (2005) Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 95:139-48
Cosman, Felicia; Nieves, Jeri; Zion, Marsha et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-75
Iida-Klein, A; Lu, S Shou; Kapadia, R et al. (2005) Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186:549-57
Kurland, Etah S; Heller, Samantha L; Diamond, Beverly et al. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15:992-7
Rubin, Mishaela R; Bilezikian, John P (2003) The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 19:415-32
Kim, Chi Hyun; Takai, Erica; Zhou, Hua et al. (2003) Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18:2116-25
Rubin, Mishaela R; Bilezikian, John P (2003) New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 32:285-307
Zhou, H; Iida-Klein, A; Lu, S S et al. (2003) Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32:513-20

Showing the most recent 10 out of 125 publications